Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA3 | P07451 | 2/20 | 0.56 |
| ▸ | CA4 | P22748 | 2/20 | 0.56 |
| ▸ | CA6 | P23280 | 2/20 | 0.56 |
| ▸ | CA5A | P35218 | 2/20 | 0.56 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6609080 | 0.87 | SMN1; SMN2 (0.55) | SMN1; SMN2GAACA12CA1CA2 | |
| SCHEMBL7629070 | 0.82 | SMN1; SMN2 (0.80) | SMN1; SMN2GAACA12CA1CA2 | |
| Water SCHEMBL27466609 | 0.78 | NR3C2 (0.62) | SMN1; SMN2GAACA12CA1CA2 | |
| SCHEMBL8390840 | 0.77 | ALDH1A1 (0.35) | SMN1; SMN2GAACA12CA1CA2 | |
| SCHEMBL1828000 | 0.76 | CA1 (0.35) | SMN1; SMN2GAACA12CA1CA2 | |
| SCHEMBL3111245 | 0.76 | ALDH1A1 (0.55) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL1570351 | 0.76 | NPSR1 (0.47) | SMN1; SMN2GAACA12CA1CA2 | |
| SCHEMBL483344 | 0.76 | ALDH1A1 (0.62) | SMN1; SMN2CA12CA1CA2CA9 | |
| SCHEMBL8908871 | 0.76 | KDM4E (0.36) | SMN1; SMN2GAACA12CA1CA2 | |
| SCHEMBL6291286 | 0.76 | POLB (0.45) | SMN1; SMN2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 595 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740493-B1 | INHIBTEURS DE L'INDOLEAMINE 2,3-DIOXYGÉNASE ET/OU DU TRYPTOPHANE DIOXYGÉNASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-01 | — | — | EP | claimed |
| CN-112694477-A | Pyrazolo ring compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-04-23 | — | — | CN | claimed |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-31 | — | — | US | claimed |
| EP-3740493-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | Idorsia Pharmaceuticals Ltd (CH) | 2020-11-25 | — | — | EP | claimed |
| CN-111601810-A | Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase | 爱杜西亚药品有限公司 | 2020-08-28 | — | — | CN | claimed |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | claimed |
| US-10106531-B2 | Compound useful to treat mycoses | PULMOCIDE LIMITED (GB) | 2018-10-23 | — | — | US | claimed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | claimed |
| CN-108419435-A | Compound and epigenetics for treating cancer | 新加坡科技研究局 | 2018-08-17 | — | — | CN | claimed |
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | claimed |
| WO-2001032628-A1 | CYANO COMPOUNDS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-05-10 | — | — | WO | claimed |
| EP-1097153-A1 | NOVEL TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-05-09 | — | — | EP | claimed |
| WO-2001005784-A1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR Xa INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-01-25 | — | — | WO | claimed |
| US-6174901-B1 | FOR TREATMENT OF RHEUMATOID ARTHRITIS, PAGETS DISEASE, OSTEOPHOROSIS, MULTIPLE MYELOMA, UVEITITIS, ACUTE OR CHRONIC MYELOGENOUS LEUKEMIA, PANCREATIC .BETA. CELL DESTRUCTION, OSTEOARTHRITIS, RHEUMATOID SPONDYLITIS, GOUTY ARTHRITIS ETC. | AMGEN INC. | 2001-01-16 | — | — | US | claimed |
| EP-1042293-A1 | SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Amgen Inc. (US) | 2000-10-11 | — | — | EP | claimed |
| WO-2000039108-A1 | THROMBIN OR FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000004021-A1 | NOVEL TRIAZOLO[4,5-d]PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-01-27 | — | — | WO | claimed |
| WO-1999032448-A1 | SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | AMGEN INC. (US) | 1999-07-01 | — | — | WO | claimed |
| EP-0793643-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-09-10 | — | — | EP | claimed |
| WO-1996016027-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-05-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | SMYD3, SMYD2, EHMT1 | SMN1; SMN2 1700/4885GAA 1438/4885CA12 3040/4885 |
| US-10106531-B2 | Compound useful to treat mycoses | DPM1, ERG28, MYC | SMN1; SMN2 3927/4885GAA 91/4885CA12 582/4885 |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDO2, TDO2, IDO1 | SMN1; SMN2 4688/4885GAA 490/4885CA12 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.